Merck & Co Inc (MRK) Company Profile & Statistics

Merck & Co Inc
MRK
(NYSE)
Closed
96.30
-2.06 (-2.09%)
in:usd•As of: Nov 15, 2024 15:59 UTC -5
After Market:96.45+0.15 (+0.16%)
Open
97.68
High
97.92
Low
94.49

About Merck & Co Inc

CEO

Robert M. Davis

Headquarters

126 east lincoln avenue

rahway, nj 07065, united states

Auditor

PricewaterhouseCoopers LLP

Employees

72,000

Share Holders

90,400

Website

www.merck.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.

Merck & Co Inc Statistics

Valuation Measures

Market Capitalization ²	243.60B
Enterprise Value	270.09B
Enterprise Value/EBITDA (ttm)	13.41
Price to Earnings Ratio (ttm)	16.19
Price to Book (mrq)	5.47
Price to Sales (ttm)	3.86
Price to Cash (ytd)	31.66

Profitability

Gross Margin (ttm)	56.89%
Operating Margin (ttm)	23.96%
Profit Margin (ttm)	13.92%
Return on Equity (ttm)	36.42%
Return on Invested Capital (ttm)	11.91%
Return on Assets (ttm)	13.68%

Income Statement

Revenue (ttm)	62.48B
Revenue Per Share (ttm)	24.65
Gross Profit (ttm)	47.02B
EBITDA (ttm)³	20.14B
Net Income Avi to Common (ttm)	13.74B
Diluted EPS (ttm)	4.77

Share Statistics

Beta (5Y Monthly)	0.40
52-Week Change	-3.73%
S&P500 52-Week Change	29.10%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	2.53B
Dividend Yield	3.20%
Float ⁴	2.53B
% Held by Insiders	0.09%
% Held by Institutions	76.07%

Balance Sheet

Total Cash (mrq)	11.35B
Total Cash Per Share (mrq)	4.48
Total Debt (mrq)	37.79B
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	N/A
Quick Ratio (mrq)	1.15%
Book Value Per Share (mrq)	N/A

Cash Flow

Operating Cash Flow Per Share (ytd)	N/A
Free Cash Flow (ytd)	0.00

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Merck & Co Inc

Trade With A Regulated Broker